YIFAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.24 CNY | +3.36% |
|
+1.38% | -10.42% |
| 25/04 | Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps | MT |
| 25/04 | Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 17,082 | 23,372 | 21,745 | 15,019 | 18,014 | 16,105 | - | - |
| Enterprise Value (EV) 1 | 17,082 | 23,372 | 21,745 | 15,019 | 18,014 | 16,105 | 16,105 | 16,105 |
| P/E ratio | 22 x | 24 x | 76.6 x | 81.7 x | -32.8 x | 29.4 x | 20.9 x | 17.5 x |
| Yield | 0.62% | 0.26% | - | - | - | - | - | - |
| Capitalization / Revenue | 3.29 x | 4.33 x | 4.93 x | - | 4.43 x | 3 x | 2.51 x | 2.18 x |
| EV / Revenue | 3.29 x | 4.33 x | 4.93 x | - | 4.43 x | 3 x | 2.51 x | 2.18 x |
| EV / EBITDA | - | - | 53 x | - | -29 x | 19.3 x | 14.9 x | 12.7 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 2.68 x | 2.77 x | 2.55 x | - | 2.19 x | 1.82 x | 1.67 x | 1.53 x |
| Nbr of stocks (in thousands) | 10,51,198 | 12,34,677 | 12,34,106 | 12,26,025 | 12,18,803 | 12,16,390 | - | - |
| Reference price 2 | 16.25 | 18.93 | 17.62 | 12.25 | 14.78 | 13.24 | 13.24 | 13.24 |
| Announcement Date | 27/02/20 | 30/03/21 | 12/04/22 | 14/04/23 | 19/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,187 | 5,400 | 4,409 | - | 4,068 | 5,367 | 6,413 | 7,377 |
| EBITDA 1 | - | - | 410.2 | - | -620.9 | 835 | 1,083 | 1,266 |
| EBIT 1 | 1,076 | 1,085 | 212.2 | - | -882.7 | 544.4 | 779.3 | 992.3 |
| Operating Margin | 20.75% | 20.08% | 4.81% | - | -21.7% | 10.14% | 12.15% | 13.45% |
| Earnings before Tax (EBT) 1 | 1,068 | 1,081 | 210.8 | - | -869 | 554.4 | 788 | 1,001 |
| Net income 1 | 903.5 | 968.4 | 278.4 | 191.3 | -551.1 | 550.6 | 774.1 | 929.9 |
| Net margin | 17.42% | 17.93% | 6.31% | - | -13.55% | 10.26% | 12.07% | 12.61% |
| EPS 2 | 0.7400 | 0.7900 | 0.2300 | 0.1500 | -0.4500 | 0.4500 | 0.6333 | 0.7567 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | 0.1000 | 0.0500 | - | - | - | - | - | - |
| Announcement Date | 27/02/20 | 30/03/21 | 12/04/22 | 14/04/23 | 19/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 12.8% | 12.2% | 3.28% | - | -6.35% | 6.16% | 7.99% | 8.78% |
| ROA (Net income/ Total Assets) | 8.67% | 8.53% | - | - | - | 4.7% | 5.9% | 6.5% |
| Assets 1 | 10,421 | 11,351 | - | - | - | 11,714 | 13,120 | 14,307 |
| Book Value Per Share 2 | 6.060 | 6.840 | 6.920 | - | 6.750 | 7.290 | 7.910 | 8.640 |
| Cash Flow per Share 2 | 0.7600 | 0.9000 | 0.2400 | - | 0.2800 | 0.0800 | 0.7700 | 0.3900 |
| Capex 1 | 865 | 715 | - | - | 499 | 442 | 458 | 466 |
| Capex / Sales | 16.68% | 13.24% | - | - | 12.27% | 8.23% | 7.14% | 6.31% |
| Announcement Date | 27/02/20 | 30/03/21 | 12/04/22 | 14/04/23 | 19/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.24
CNY
Average target price
19
CNY
Spread / Average Target
+43.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.42% | 2.23B | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.32% | 13.79B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- 002019 Stock
- Financials Yifan Pharmaceutical Co., Ltd.
